Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line
Reads0
Chats0
TLDR
Novel evidence is provided that extensive impairment in pEGFR endocytosis via the early endocytic pathway might confer gefitinib-resistance in NSCLC cell lines, and an aberration in some steps of EGF-EGFR trafficking from the early endsomes to late endosomes/lysosomes occurs in QG56 cells.Abstract:
Gefitinib (Iressa)–a specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase–has been shown to suppress the activation of EGFR signaling required for cell survival and proliferation in non-small cell lung cancer (NSCLC) cell lines. We recently provided novel evidence that gefitinib-sensitive PC9 cells show normal endocytosis of EGFR: internalized EGF-EGFR complexes were transported to late endosomes/lysosomes 15 min after EGF stimulation, and then degraded within the lysosomes. However, gefitinib-resistant QG56 cells showed internalized EGFR accumulation in early endosomes after 60 min of internalization, instead of its trafficking to lysosomes, indicating an aberration in some steps of EGF-EGFR trafficking from the early endosomes to late endosomes/lysosomes. Therefore, we postulate that impairment in some steps of EGF-EGFR trafficking from early endosomes to late endosomes/lysosomes might confer gefitinib-resistance in NSCLC cell lines. To further substantiate the detailed internalization mechanism of gefitinib-sensitive and gefitinib-resistant cells, using confocal immunofluorescence microscopy, we examined the endocytic trafficking of phosphorylated EGFR (pEGFR) in the absence or presence of gefitinib. In PC9 and QG56 cells without EGF stimulation, a large number of pEGFR-positive small vesicular structures not colocalized with late endosomes/lysosomes were spread throughout the cytoplasm, and some pEGFR staining was distributed in the nucleus. This implies a novel intracellular trafficking pathway for pEGFR from cytoplasmic vesicles to the nucleus. Furthermore, an aggregated vesicular structure of early endosomes was observed in the perinuclear region of QG56 cells; it was revealed to be associated with SNX1, originally identified as a protein that interacts with EGFR. Therefore, we confirmed our previous data that an aberration in some steps of EGF-EGFR trafficking from the early endosomes to late endosomes/lysosomes occurs in QG56 cells. Furthermore, in PC9 cells, efficient phosphorylation of EGFR and rapid internalization of pEGFR was observed at 3 min after EGF stimulation; these internalized pEGFR-positive vesicles were trafficked to late endosomes at 15 min, indicating rapid trafficking of EGF-pEGFR complexes from early to late endosomes in PC9 cells. Gefitinib treatment strongly reduced the phosphorylation level of EGFR, and subsequent endocytosis of EGFR was significantly suppressed in PC9 cells. In contrast, in QG56 cells, EGFR trafficking via the early endocytic pathway was basically impaired; therefore, gefitinib appeared to slightly suppress the internalization of pEGFR. Collectively, our data provide novel evidence that extensive impairment in pEGFR endocytosis via the early endocytic pathway might confer gefitinib-resistance in QG56 cells.read more
Citations
More filters
Journal ArticleDOI
Insights into the PX (phox-homology) domain and SNX (sorting nexin) protein families: structures, functions and roles in disease
TL;DR: An overview of the PX domain proteins is presented, incorporating recent functional and structural insights, and an updated classification of the proteins into distinct subfamilies is proposed on the basis of these insights.
Journal Article
The nuclear epidermal growth factor receptor signaling network and its role in cancer
TL;DR: The current knowledge of the nuclear EGFR signaling network is summarized, including how it is trafficked to the nucleus, the functions it serves inThe nucleus, and how these functions impact cancer progression, survival, and response to chemotherapeutics.
Journal ArticleDOI
Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells
Wei Chien Huang,Yun Ju Chen,Long Yuan Li,Ya Ling Wei,Sheng Chieh Hsu,Shing Ling Tsai,Pei Chun Chiu,Wei-Pang Huang,Ying Nai Wang,Chung-Hsuan Chen,Wei Chao Chang,Wei Chao Chang,Wen Chang Chang,Andy Jer En Chen,Chang Hai Tsai,Chang Hai Tsai,Mien Chie Hung,Mien Chie Hung +17 more
TL;DR: Light is shed on the role of nuclear EGFR in the sensitivity of wtEGFR-expressing cancer cells to EGFR tyrosine kinase inhibitors and a putative molecular mechanism contributing to gefitinib resistance through BCRP/ABCG2 expression is deciphered.
Journal ArticleDOI
Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.
Carolien Boeckx,Marc Baay,An Wouters,Pol Specenier,Jan B. Vermorken,Marc Peeters,Filip Lardon +6 more
TL;DR: An improved understanding of the molecular mechanisms of resistance to EGFR inhibitors may provide valuable indications to identify biomarkers that can be used clinically to predict response to EG FR blockade and to establish new treatment options to overcome resistance.
Journal ArticleDOI
Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
Yun Ju Chen,Wei Chien Huang,Ya Ling Wei,Sheng Chieh Hsu,Ping Yuan,Heather Lin,Ignacio I. Wistuba,J. Jack Lee,Chia Jui Yen,Wu Chou Su,Kwang Yu Chang,Wen Chang Chang,Tse-Chuan Chou,Tse-Chuan Chou,Chao Kai Chou,Chang Hai Tsai,Chang Hai Tsai,Mien Chie Hung +17 more
TL;DR: It is shown that acquired resistance of wtEGFR-expressing cancer cells to an EGFR TKI, gefitinib, is associated with elevated expression of breast cancer resistance protein (BCRP/ABCG2), which in turn leads to gefITinib efflux from cells.
References
More filters
Journal ArticleDOI
Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival
Hui-Wen Lo,Mien Chie Hung +1 more
TL;DR: A better understanding of the physiological and malignant nature of the nuclear EGFR pathway will likely shed light into the biology of cancer with nuclear RTKs.
Journal ArticleDOI
ZD1839 (‘Iressa’)1,2 as an Anticancer Agent
José Baselga,Steven D. Averbuch +1 more
TL;DR: Preliminary results from phase I trials in patients with advanced disease and a wide variety of tumour types suggest that ZD1839 has an acceptable tolerability profile and promising clinical efficacy, particularly in non-small cell lung cancer (NSCLC).
Journal ArticleDOI
Correction: Sorting out the cellular functions of sorting nexins
Carolyn A. Worby,Jack E. Dixon +1 more
TL;DR: The authors would like to apologize for the following omissions: the following reference should have been included in the reference list: Ref. 92, references 92 and 92.
Journal Article
Cellular targets of gefitinib
Dirk Brehmer,Zoltán Greff,Klaus Godl,Stephanie Blencke,Alexander Kurtenbach,Martina Weber,Stefan Müller,Bert Klebl,Matthew Cotten,György Kéri,Josef Wissing,Henrik Daub +11 more
TL;DR: A proteomic method is used to profile the cellular targets of the clinical epidermal growth factor receptor kinase inhibitor gefitinib and suggestions are suggested that suggest alternative cellular modes of action for gefITinib.
Journal ArticleDOI
The ErbB receptor family: a therapeutic target for cancer
TL;DR: Preliminary results will be discussed of studies of the first generation of therapeutics to enter clinical evaluation in malignant diseases and potential advantages and disadvantages of these different therapeutic modalities, as well as future challenges of evaluating ErbB-targeted agents in the clinic.
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman,Kreshnik Zejnullahu,Tetsuya Mitsudomi,Youngchul Song,Courtney Hyland,Joon Oh Park,Neal I. Lindeman,Christopher-Michael Gale,Xiaojun Zhao,James J. Christensen,Takayuki Kosaka,Alison J. Holmes,Andrew M. Rogers,Federico Cappuzzo,Tony Mok,Charles Lee,Bruce E. Johnson,Lewis C. Cantley,Pasi A. Jänne +18 more